Real world effectiveness of sotrovimab in preventing COVID-19-related hospitalisation or death in patients infected with Omicron BA.2.

Real world effectiveness of sotrovimab in preventing COVID-19-related hospitalisation or death in patients infected with Omicron BA.2.

Publication date: Feb 01, 2024

Laboratory-based evidence indicates that neutralization of the BA. 2 (Omicron) variant by sotrovimab is reduced versus previous SARS-CoV-2 variants. Since there is a lack of real-world data, we investigated whether sotrovimab has reduced clinical efficacy against the BA. 2 variant. We performed a prospective cohort study using real-world data from 1180 randomly-selected BA. 2 variant-infected patients. Follow-up to study endpoints averaged 29 days. For mild cases (not requiring oxygen-supplementation), primary outcomes were requiring O-supplementation, intensive care unit (ICU) admission or death. For moderate-to-severe COVID-19 cases (requiring oxygen-supplementation other than mechanical ventilation), the primary outcome was ICU admission or death. Patients in the sotrovimab group (n = 569) and control patients (n = 611) were included. Sotrovimab-treated patients versus controls had reduced risk of death (0. 4% vs 6. 4%, p

Concepts Keywords
Covid Omicron BA.2 variant
Death SARS-CoV-2
Drugs Sotrovimab
Hospitalisation

Semantics

Type Source Name
disease VO effectiveness
disease MESH COVID-19
disease MESH death
disease VO LACK
drug DRUGBANK Oxygen

Original Article

(Visited 1 times, 1 visits today)